Schizophrenia Treatment with Second-Generation Antipsychotics: A Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain
Benjamin Kearns, Katy Cooper, Anna Cantrell, Chloe Thomas School of Health and Related Research, The University of Sheffield, Sheffield, UKCorrespondence: Benjamin Kearns Email b.kearns@sheffield.ac.ukPurpose: Cardiovascular and metabolic adverse events are costly to treat, and their incidence is in...
Guardado en:
Autores principales: | Kearns B, Cooper K, Cantrell A, Thomas C |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e5ce207ca0524f62a7e45bc7d7d3a3d3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Gender Differences in the First-Year Antipsychotic Treatment for Chinese First-Episode Schizophrenia
por: Pu C, et al.
Publicado: (2020) -
Antipsychotic medication-mediated cognitive change in schizophrenia and polygenic score for cognitive ability
por: Rachael K. Blackman, et al.
Publicado: (2022) -
Association study between COMT, DRD2, and DRD3 gene variants and antipsychotic treatment response in Mexican patients with schizophrenia
por: Escamilla R, et al.
Publicado: (2018) -
Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection
por: Fitzgerald HM, et al.
Publicado: (2021) -
Antipsychotic-associated weight gain: management strategies and impact on treatment adherence
por: Dayabandara M, et al.
Publicado: (2017)